CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 900 enrolled
Drug / intervention
Yellow fever vaccine, Institut Pasteurbiological
Likely dose
Yellow fever vaccine, Institut Pasteur 500IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04059471
NCT04059471Phase 4Completed

Non- Inferiority Fractional-doses Trial for Yellow Fever Vaccine

University of Oxford·interventional·Posted Aug 16, 2019·Updated Feb 9, 2024

In Brief

A Phase 4 clinical trial evaluating Yellow fever vaccine, Institut Pasteur for Yellow Fever. Completed, enrolled 900 participants across 2 sites in 2 countries.

Detailed Summary

In the recent past there has been a number of large urban Yellow Fever outbreaks in sub-Saharan Africa, tropical South Americas, The demand for Yellow Fever vaccines in response to the large urban outbreaks occurring concurrently and the risk of further spread through Africa and to Asia was larger than the available global supply. In this situation, the World Health Organisation (WHO) developed recommendations for the use of fractional doses of Yellow Fever vaccine as a dose-sparing strategy. These recommendations were based on data from a limited number of clinical trials, none of which had been conducted in Africa. This was due to the uncertainties on the minimum dose requirement. Our study complements a study which is comparing full standard dose to 1/5th of standard dose of all four WHO-prequalified YF vaccines in adults (ClinicalTrials.gov number: NCT02991495), and is currently ongoing at KEMRI CGMRC and Epicentre, Mbarara which is designed to answer questions on the use of current stock of YF vaccines with a potency as close as possible to each manufacturers' minimum release. Data from this trial will inform a WHO recommendation on using 1/5th of the current standard dose of vaccine for outbreak control. However, since many vials will contain excess YF vaccine such that 1/5th of a vial is likely to be substantially above the current minimum potency requirements, these data may not be scientifically explanatory regarding the minimum dose required for preventive use. The new complementary study, aims to determine the lowest YF vaccine dose that is non-inferior to the current standard full dose among populations in sub-Saharan Africa. The study will be conducted in Kenya (KEMRI Center for Geographical Medicine Research-Coast (CGMR-C), Kilifi) and Uganda (Epicentre, Mbarara) with trial participants recruited at both sites, using vaccine from one WHO-prequalified manufacturer (Institut Pasteur de Dakar, Senegal (IPD)).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsYellow Fever
CountriesKenya, Uganda

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedAug 16, 2019
Enrollment StartNov 11, 2019
Primary CompletionMar 30, 2020
Study CompletionJun 24, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.9 years ago

Interventions

Yellow fever vaccine, Institut Pasteurbiological

Full dose and 500IU/dose